Abstract
Globally, ovarian cancer is one of the most common cancers in women and one of the most common causes of cancer death. Researchers have been committed to investigating new treatment methods for ovarian cancer. In the present study, a new nano-siRNA delivery system loaded with anti-ESR1 siRNA was designed and synthesized. Its clinical and nursing value for ovarian cancer was evaluated, and the related mechanism was explored. First, the inhibitory activity of the new compound on the viability of ovarian cancer was measured via CCK-8 assay. Second, the relative expression of the estrogen receptor in the ovarian cancer cells was determined through real-time RT-PCR detection. Results revealed that the novel nano-siRNA delivery system loaded with anti-ERα siRNA could negatively regulate the expression of ERα and suppress the progression of ovarian cancer.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
